PDCD1 and skin squamous cell carcinoma: Recent advances in immune checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 antibodies, have shown noteworthy efficacy in the treatment of advanced cSCC (Miller et al., 2017[127]).